Psoriasis Therapeutics in Asia-Pacific Markets reach $1.2 billion to 2021: Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth
ResearchMoz added Latest Research Report titled " Psoriasis Therapeutics in Asia-Pacific Markets to 2021: Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth " to it's Large Report database.
GBI Research, the leading business intelligence provider, has released its latest research, "" Psoriasis Therapeutics in Asia-Pacific Markets to 2021: Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth "", which provides insights into psoriasis therapeutics in the Asia-Pacific (APAC) market. For the purposes of this report, APAC refers to the market in China, India, Japan, and Australia only. The report estimates the market size for 2014, along with forecasts until 2021. It also covers disease epidemiology, treatment algorithms, treatment use patterns, in-depth analysis of pipeline molecules, clinical trial failure rates, and analysis of recent deals. It is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis carried out by GBI Research’s team of industry experts.
Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=285644
In 2014, the value of the psoriasis therapeutics market in APAC amounted to an estimated $690m, and it is forecast to grow at a Compound Annual Growth Rate (CAGR) of 8.4% between 2014 and 2021 to reach $1.2 billion. The psoriasis treatment landscape is a particularly complex one. More than 80% of patients fall into the mild-or-moderate category, for which the first line of treatment is topical drugs, phototherapy, or a combination. In the case of severe patients, non-steroidal drugs such as methotrexate, cyclosporine, and acitretin are practiced as first-line treatment; however, they come with toxicity concerns and so cannot be prescribed for long durations. Biologics such as TNF inhibitors (adalimumab, etanercept, infliximab) and ustekinumab are largely prescribed as second-line therapy when none of the aforementioned options provide the desired results. However, during the forecast period, biologics are likely gain a significant patient share due to healthcare plans in APAC and awareness regarding the effectiveness of biologics.
Read All Pharmaceutical Market Research Reports @ http://www.researchmoz.us/pharmaceutical-market-reports-38.html
Table of Contents
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 9
2.1 Symptoms 10
2.1.1 Skin Manifestations 10
2.1.2 Psychological Impact 10
2.2 Etiology, Co-morbidities and Risk Factors 10
2.2.1 Genetics 10
2.2.2 Psoriatic Arthritis 10
2.2.3 Mental Health Disorders 10
2.2.4 Metabolic Syndrome, Smoking, Diet and Alcohol Consumption 11
2.2.5 Infections 11
2.2.6 Köebner Phenomenon 11
2.2.7 Other Immune-Mediated Diseases 12
2.3 Pathophysiology 12
2.4 Diagnosis 12
2.5 Epidemiology 13
2.6 Treatment and Management 14
2.6.1 Pharmacological Therapies 15
2.6.2 Non-pharmacological Therapies 16
2.6.3 Combination and Rotational Therapies 16
2.6.4 Quality of Life Assessments 16
2.6.5 Summary 17
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket
Albany NY - 12207
United States
Tel: +1-518-621-2074
Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
GBI Research, the leading business intelligence provider, has released its latest research, "" Psoriasis Therapeutics in Asia-Pacific Markets to 2021: Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth "", which provides insights into psoriasis therapeutics in the Asia-Pacific (APAC) market. For the purposes of this report, APAC refers to the market in China, India, Japan, and Australia only. The report estimates the market size for 2014, along with forecasts until 2021. It also covers disease epidemiology, treatment algorithms, treatment use patterns, in-depth analysis of pipeline molecules, clinical trial failure rates, and analysis of recent deals. It is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis carried out by GBI Research’s team of industry experts.
Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=285644
In 2014, the value of the psoriasis therapeutics market in APAC amounted to an estimated $690m, and it is forecast to grow at a Compound Annual Growth Rate (CAGR) of 8.4% between 2014 and 2021 to reach $1.2 billion. The psoriasis treatment landscape is a particularly complex one. More than 80% of patients fall into the mild-or-moderate category, for which the first line of treatment is topical drugs, phototherapy, or a combination. In the case of severe patients, non-steroidal drugs such as methotrexate, cyclosporine, and acitretin are practiced as first-line treatment; however, they come with toxicity concerns and so cannot be prescribed for long durations. Biologics such as TNF inhibitors (adalimumab, etanercept, infliximab) and ustekinumab are largely prescribed as second-line therapy when none of the aforementioned options provide the desired results. However, during the forecast period, biologics are likely gain a significant patient share due to healthcare plans in APAC and awareness regarding the effectiveness of biologics.
Read All Pharmaceutical Market Research Reports @ http://www.researchmoz.us/pharmaceutical-market-reports-38.html
Table of Contents
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 9
2.1 Symptoms 10
2.1.1 Skin Manifestations 10
2.1.2 Psychological Impact 10
2.2 Etiology, Co-morbidities and Risk Factors 10
2.2.1 Genetics 10
2.2.2 Psoriatic Arthritis 10
2.2.3 Mental Health Disorders 10
2.2.4 Metabolic Syndrome, Smoking, Diet and Alcohol Consumption 11
2.2.5 Infections 11
2.2.6 Köebner Phenomenon 11
2.2.7 Other Immune-Mediated Diseases 12
2.3 Pathophysiology 12
2.4 Diagnosis 12
2.5 Epidemiology 13
2.6 Treatment and Management 14
2.6.1 Pharmacological Therapies 15
2.6.2 Non-pharmacological Therapies 16
2.6.3 Combination and Rotational Therapies 16
2.6.4 Quality of Life Assessments 16
2.6.5 Summary 17
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket
Albany NY - 12207
United States
Tel: +1-518-621-2074
Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Psoriasis Therapeutics in Asia-Pacific Markets reach $1.2 billion to 2021: Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth
![Psoriasis Therapeutics in Asia-Pacific Markets reach $1.2 billion to 2021: Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth]()
Reviewed by Sagar Jagtap
on
02:17
Rating:
No comments: